Chan, Antonia http://orcid.org/0000-0002-7496-9581
Torelli, Stefan
Cheng, Evaline
Batchelder, Ryan
Waliany, Sarah
Neal, Joel
Witteles, Ronald
Nguyen, Patricia
Cheng, Paul
Zhu, Han
Funding for this research was provided by:
National Institute of Health (1K08HL1614050, K08-HL153798)
American Heart Association (20CDA35310303)
Joan and Sanford I Weill Scholar Award
Article History
Accepted: 27 October 2023
First Online: 15 December 2023
Compliance with Ethical Standards
:
: Ronald Witteles serves as an advisory board participant for Pfizer, Alnylam, Ionis, AstraZeneca, Janssen, Intellia, NovoNordisk, and Alexion. Joel Neal reports personal fees from AstraZeneca, Exelixis, Eli Lilly and Company, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Sanofi/Regeneron, D2G Oncology, Surface Oncology, Turning Point Therapeutics, Mirati Therapeutics, Gilead Sciences, Summit Therapeutics; personal fees and other from Genentech/Roche, Takeda Pharmaceuticals, Abbvie, Novartis, Novocure; other from Merck, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Adaptimmune, GSK, Janssen, CME Matters, Clinical Care Options CME, Research to Practice CME, Medscape CME, Biomedical Learning Institute CME, MLI Peerview CME, Prime Oncology CME, Projects in Knowledge CME, Rockpointe CME, MJH Life Sciences CME, Medical Educator Consortium, and HMP Education. Sarah Waliany serves as a consultant for AstraZeneca. The remaining authors declare no competing interests.
: This article does not contain any studies with human or animal subjects performed by any of the authors.